SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+11.91%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$173M
AUM Growth
+$173M
(+84,096%)
Cap. Flow
+$22.9M
Cap. Flow
% of AUM
13.3%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
115
New
19
Increased
26
Reduced
33
Closed
31
Top Buys
| 1 |
Fulcrum Therapeutics
FULC
|
$5.24M |
| 2 |
Cogent Biosciences
COGT
|
$4.03M |
| 3 |
Cerus
CERS
|
$3.66M |
| 4 |
Arvinas
ARVN
|
$3.06M |
| 5 |
NextCure
NXTC
|
$2.94M |
Top Sells
Sector Composition
| 1 | Healthcare | 93.23% |
| 2 | Financials | 4.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.6M | 4.86% |
61,897
+5,271
| +9% | +$732K |
|
2
Veracyte
VCYT
$2.39B
| $8.34M | 4.72% |
179,548
+28,687
| +19% | +$1.33M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.13M | 4.59% |
45,941
+8,188
| +22% | +$1.45M |
|
4
Merus
MRUS
$4.98B
| $7.61M | 4.3% |
345,964
+25,149
| +8% | +$553K |
|
|
AMYT
5
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $6.22M | 3.52% |
516,221
+59,684
| +13% | +$719K |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.75M | 3.25% |
52,469
+2,434
| +5% | +$267K |
|
|
7
Cogent Biosciences
COGT
$1.69B
| $5.7M | 3.22% |
677,900
+479,655
| +242% | +$4.03M |
|
8
Immatics
IMTX
$619M
| $5.69M | 3.22% |
437,866
+148,458
| +51% | +$1.93M |
|
|
9
Fulcrum Therapeutics
FULC
$351M
| $5.24M | 2.96% |
+185,691
| New | +$5.24M |
|
|
10
NextCure
NXTC
$13.5M
| $4.86M | 2.75% |
721,302
+435,804
| +153% | +$2.94M |
|
11
Insmed
INSM
$28.8B
| $4.81M | 2.72% |
174,588
-2,845
| -2% | -$78.3K |
|
|
RACB
12
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $4.66M | 2.64% |
473,396
-22,459
| -5% | -$221K |
|
13
United Therapeutics
UTHR
$13.8B
| $3.91M | 2.21% |
21,189
+5,900
| +39% | +$1.09M |
|
|
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.8M | 2.15% |
101,890
-11,368
| -10% | -$424K |
|
|
15
Cerus
CERS
$251M
| $3.77M | 2.13% |
619,369
+600,678
| +3,214% | +$3.66M |
|
|
IMGN
16
DELISTED
Immunogen Inc
IMGN
| $3.69M | 2.08% |
649,919
-177,668
| -21% | -$1.01M |
|
|
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.58M | 2.03% |
163,486
+24,181
| +17% | +$530K |
|
|
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.27M | 1.85% |
57,704
-46,154
| -44% | -$2.61M |
|
19
iTeos Therapeutics
ITOS
$449M
| $3.16M | 1.78% |
116,931
+41,420
| +55% | +$1.12M |
|
20
Aclaris Therapeutics
ACRS
$209M
| $3.12M | 1.76% |
173,327
-15,392
| -8% | -$277K |
|
|
21
Arvinas
ARVN
$568M
| $3.06M | 1.73% |
+37,249
| New | +$3.06M |
|
22
Leap Therapeutics
LPTX
$12M
| $2.49M | 1.41% |
+620,000
| New | +$2.49M |
|
23
Halozyme
HALO
$8.56B
| $2.45M | 1.38% |
60,170
-6,503
| -10% | -$265K |
|
|
BLU
24
DELISTED
BELLUS Health Inc.
BLU
| $2.24M | 1.27% |
365,000
+155,067
| +74% | +$952K |
|
25
MoonLake Immunotherapeutics
MLTX
$3.54B
| $2.22M | 1.26% |
223,906
-10,114
| -4% | -$100K |
|